1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/60917
Full metadata record
DC FieldValueLanguage
dc.creatorLuciana Mendes Araújo Borémpt_BR
dc.creatorSergio Henrique Sousa Santospt_BR
dc.creatorDaniela Fernanda de Freitaspt_BR
dc.creatorAmanda Souto Machadopt_BR
dc.creatorAlanna Fernandes Paraisopt_BR
dc.creatorBruna Viana Caldaspt_BR
dc.creatorJoão Felício Rodrigues Netopt_BR
dc.creatorJuliana Pinto Limapt_BR
dc.creatorAndré Luiz Senna Guimarãespt_BR
dc.creatorAlfredo Mauricio Batista de Paulapt_BR
dc.date.accessioned2023-11-13T22:35:49Z-
dc.date.available2023-11-13T22:35:49Z-
dc.date.issued2022-09-14-
dc.citation.volume12pt_BR
dc.citation.issue55pt_BR
dc.citation.spage1pt_BR
dc.citation.epage12pt_BR
dc.identifier.doihttps://doi.org/10.1186/s43066-022-00216-wpt_BR
dc.identifier.issn2090-6226pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/60917-
dc.description.resumoBackground Telmisartan is a non-peptide angiotensin II receptor antagonist which acts by ACE/AngII/AT1 axis blockade (ARB). In the last years increasing evidence of its metabolic benefits pointed out this drug as the most promising ARB for nonalcoholic fatty liver disease (NAFLD) treatment. The aim of the present study was to investigate the Telmisartan effect on treating NAFLD in mice fed with a high-fat diet evaluating liver gene modulation. Twenty-four male mice were divided into four groups and fed for 60 days with a standard diet (ST), standard diet plus TEL (ST+TEL 5 mg/kg/day by gavage for 4 weeks), high-fat diet (HFD), or high-fat diet plus TEL (HFD+TEL 5 mg/kg/day by gavage for 4 weeks). Body weight, lipid profile, insulin, alanine transaminase, and aspartate aminotransferase were evaluated. Liver histology was analyzed. US imaging was performed to access liver dimension and echogenicity and also epididymal fat pad thickness. The expression of proinflammatory resistin/TRL4/MYD88 pathway was analyzed. Results The main findings showed that TEL reduced the resistin, TRL4, and Myd88 liver expression in the HFD + TEL group when compared to the obese control group (HFD). Decreased hepatic steatosis in the HFD + TEL group demonstrated by US measurements of the liver longitudinal axis and echogenicity were observed. In addition, TEL reduced epididymal adipose pad thickness, body weight, transaminases, and improved glucose tolerance test and HDL cholesterol. Conclusions We observed that Telmisartan treatment improved metabolism, decreasing NAFLD.pt_BR
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Geraispt_BR
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentICA - INSTITUTO DE CIÊNCIAS AGRÁRIASpt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofEgyptian Liver Journalpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectRenin-angiotensin systempt_BR
dc.subjectObesitypt_BR
dc.subjectAngiotensin-(1–7)pt_BR
dc.subjectNon-alcoholic fatty liver diseasept_BR
dc.subject.otherObesidadept_BR
dc.subject.otherFígadopt_BR
dc.titleAngiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expressionpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://eglj.springeropen.com/articles/10.1186/s43066-022-00216-w#rightslinkpt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-7788-5447pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Angiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression.pdf1.32 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.